Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli–Leydig cell tumour, microcystic stromal tumour and their mimics

Joseph T. Rabban, Anthony N. Karnezis, W. Patrick Devine

Research output: Contribution to journalReview article


Within the last decade, molecular advances have provided insights into the genetics of several ovarian sex cord–stromal tumours that have otherwise been enigmatic. Chief among these advances are the identification of FOXL2, DICER1 and CTNNB1 mutations in adult granulosa cell tumours, Sertoli–Leydig cell tumours (SLCTs), and microcystic stromal tumours (MCSTs), respectively. As access to molecular diagnostic laboratories continues to become more widely available, the potential roles for tumour mutation testing in the pathological diagnosis of these tumours merit discussion. Furthermore, links to inherited cancer susceptibility syndromes may exist for some women with SLCT (DICER1 syndrome) and MCST [familial adenomatous polyposis (FAP)]. This review will address practical issues in deciding when and how to apply mutation testing in the diagnosis of these three sex cord–stromal tumours. The pathologist's role in recommending referral for formal risk assessment for DICER1 syndrome and FAP will also be discussed.

Original languageEnglish (US)
Pages (from-to)11-24
Number of pages14
Issue number1
StatePublished - Jan 1 2020



  • CTNNB1
  • DICER1
  • FOXL2
  • granulosa cell tumour
  • microcystic stromal tumour
  • Sertoli–Leydig cell tumour

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this